← Latest news 
Zydus Lifesciences buys Assertio for 166 million to boost US specialty oncology reach
Business
Published on 13 May 2026
The deal brings a key cancer drug and network
Zydus Lifesciences has agreed to acquire Assertio Holdings for $166.40 million, a move aimed at strengthening its position in the U.S. specialty oncology market. The acquisition includes Assertio’s cancer treatment Rolvedon and adds a commercial network that Zydus expects to use to expand and accelerate its oncology initiatives.
- Zydus will pay $166.40 million for Assertio Holdings
- The deal includes the oncology drug Rolvedon
- Zydus gains a U.S. commercial network to scale oncology efforts
- Transaction targets growth in specialty cancer care in the US
Read the full story at The Economic Times
This summarization was done by Beige for a story published on 
The Economic Times